FluMa peptide

FluMa peptide is a peptide-based biologic immunostimulant initially developed by the Centre Hospitalier Universitaire Vaudois (CHUV). While detailed public records under the specific name 'FluMa peptide' are limited, it is widely recognized in clinical research as the HLA-A*0201-restricted epitope from the Influenza A virus matrix protein M1 (residues 58-66, sequence GILGFVFTL). It is primarily utilized in CHUV-led clinical trials as a potent activator of memory CD8+ T cells, often serving as a control antigen or a component of multi-peptide vaccines for melanoma to enhance or monitor the patient's immune response. The peptide functions by binding to HLA-A*0201 molecules, which then present the antigen to T-cell receptors, triggering an immunostimulatory effect.

Other names

Flu-MaFlu M1 peptideInfluenza Matrix protein M1 (58-66) peptideGILGFVFTL